Pancreatic Ductal Adenocarcinoma

Oncology
19
Pipeline Programs
15
Companies
27
Clinical Trials
12 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
3
6
1
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
267%
Monoclonal Antibody
133%
+ 19 programs with unclassified modality

Competitive Landscape

15 companies ranked by most advanced pipeline stage

GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
Immuncell-LCPhase 31 trial
Active Trials
NCT04969731RecruitingEst. Jun 2027
Bristol Myers Squibb
2 programs
1
1
BMS-986504Phase 2/35 trials
SX-682Phase 11 trial
Active Trials
NCT04477343Recruiting20Est. Dec 2026
NCT07283705Suspended60Est. Oct 2031
NCT07063745Recruiting590Est. Aug 2031
+3 more trials
Ipsen
IpsenChina - Tianjin
3 programs
2
1
NALIRIFOXPhase 21 trial
111In-IPN01087 Low dosePhase 11 trial
177Lu-3BP-227Phase 11 trial
Active Trials
NCT04632199Withdrawn0Est. Dec 2021
NCT03525392Terminated14Est. Apr 2021
NCT05851924Recruiting60Est. May 2026
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
AbemaciclibPhase 2Small Molecule1 trial
Active Trials
NCT02981342Completed106Est. Nov 2018
Genentech
GenentechCA - Oceanside
1 program
1
AtezolizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03979066Terminated1Est. Nov 2019
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
1
ChiauranibPhase 2Small Molecule1 trial
Active Trials
NCT06492915RecruitingEst. Jul 2026
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
INNO-206Phase 21 trial
Active Trials
NCT01580397Completed15Est. Jul 2013
Arcus Biosciences
1 program
1
Stereotactic body radiotherapyPhase 21 trial
Active Trials
NCT06048484RecruitingEst. Apr 2027
Elicio Therapeutics
2 programs
1
ELI-002 7PPhase 1/21 trial
ELI-002 7PN/A1 trial
Active Trials
NCT07083479Available
NCT05726864Active Not RecruitingEst. Nov 2026
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
AFNT-211Phase 1/21 trial
Active Trials
NCT06105021Active Not RecruitingEst. Dec 2029
NP
Nelum PharmaNC - Cary
1 program
1
GemcitabinePhase 1/21 trial
Active Trials
NCT04827953Active Not Recruiting28Est. Apr 2025
Novartis
NovartisBASEL, Switzerland
3 programs
3
68Ga-FF58Phase 11 trial
68Ga-NNS309Phase 11 trial
[68Ga]Ga-NNS309Phase 11 trial
Active Trials
NCT05977322Terminated24Est. Dec 2024
NCT07261631Recruiting180Est. May 2029
NCT06562192Recruiting162Est. Jan 2031
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
2
BI 765883Phase 11 trial
VSV-GP154Phase 11 trial
Active Trials
NCT06528093Terminated8Est. Jun 2025
NCT05846516Active Not Recruiting58Est. Jun 2027
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
Activity MonitorN/A1 trial
Active Trials
NCT04400903Terminated110Est. Sep 2022
Ambry Genetics
Ambry GeneticsCA - Aliso Viejo
1 program
Multi-gene Next Generation Sequencing PanelN/A1 trial
Active Trials
NCT02790944CompletedEst. Aug 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GC BiopharmaImmuncell-LC
Bristol Myers SquibbBMS-986504
Bristol Myers SquibbBMS-986504
Bristol Myers SquibbBMS-986504
Bristol Myers SquibbBMS-986504
Chipscreen BiosciencesChiauranib
Arcus BiosciencesStereotactic body radiotherapy
IpsenNALIRIFOX
GenentechAtezolizumab
Eli Lilly and CompanyAbemaciclib
ImmunityBioINNO-206
T-TherapeuticsAFNT-211
Elicio TherapeuticsELI-002 7P
Nelum PharmaGemcitabine
Novartis68Ga-NNS309

Showing 15 of 26 trials with date data

Clinical Trials (27)

Total enrollment: 2,076 patients across 27 trials

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Start: Sep 2021Est. completion: Jun 2027
Phase 3Recruiting

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Start: Jan 2026Est. completion: Aug 2031590 patients
Phase 2/3Recruiting

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Start: Oct 2025Est. completion: May 2029470 patients
Phase 2/3Recruiting

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Start: May 2026Est. completion: Oct 203160 patients
Phase 2Suspended

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Start: Sep 2025Est. completion: Dec 2031130 patients
Phase 2Recruiting

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Start: Aug 2024Est. completion: Jul 2026
Phase 2Recruiting
NCT06048484Arcus BiosciencesStereotactic body radiotherapy

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Start: May 2024Est. completion: Apr 2027
Phase 2Recruiting

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Start: May 2023Est. completion: May 202660 patients
Phase 2Recruiting

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

Start: Nov 2019Est. completion: Nov 20191 patients
Phase 2Terminated

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

Start: Jan 2017Est. completion: Nov 2018106 patients
Phase 2Completed

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Start: May 2012Est. completion: Jul 201315 patients
Phase 2Completed

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Start: Mar 2024Est. completion: Dec 2029
Phase 1/2Active Not Recruiting

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Start: Apr 2023Est. completion: Nov 2026
Phase 1/2Active Not Recruiting

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Start: Sep 2021Est. completion: Apr 202528 patients
Phase 1/2Active Not Recruiting

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Start: Nov 2025Est. completion: May 2029180 patients
Phase 1Recruiting

A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors

Start: Oct 2025Est. completion: Jan 202732 patients
Phase 1Recruiting

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Start: Mar 2025Est. completion: Apr 20268 patients
Phase 1Recruiting

A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Start: Oct 2024Est. completion: Jun 20258 patients
Phase 1Terminated
NCT06562192Novartis[68Ga]Ga-NNS309

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Start: Oct 2024Est. completion: Jan 2031162 patients
Phase 1Recruiting

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

Start: Oct 2023Est. completion: Dec 202424 patients
Phase 1Terminated

A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer

Start: May 2023Est. completion: Jun 202758 patients
Phase 1Active Not Recruiting
NCT04632199Ipsen111In-IPN01087 Low dose

Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.

Start: Mar 2021Est. completion: Dec 20210
Phase 1Withdrawn

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Start: Nov 2020Est. completion: Dec 202620 patients
Phase 1Recruiting
NCT03525392Ipsen177Lu-3BP-227

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Start: May 2018Est. completion: Apr 202114 patients
Phase 1Terminated

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

N/AAvailable

Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

Start: Sep 2020Est. completion: Sep 2022110 patients
N/ATerminated
NCT02790944Ambry GeneticsMulti-gene Next Generation Sequencing Panel

Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer

Start: May 2016Est. completion: Aug 2020
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
12 actively recruiting trials targeting 2,076 patients
15 companies competing in this space